Literature DB >> 31171445

Neoadjuvant therapy for melanoma: is it ready for prime time?

Beth Helmink1, Jennifer A Wargo2.   

Abstract

Entities:  

Year:  2019        PMID： 31171445     DOI： 10.1016/S1470-2045(19)30377-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Immune checkpoint inhibition: from molecules to clinical application.

Authors:  L S Taams; T D de Gruijl
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

2.  Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma.

Authors:  Run-Cong Nie; Shu-Qiang Yuan; Yun Wang; Ying-Bo Chen; Yan-Yu Cai; Shi Chen; Shu-Man Li; Jie Zhou; Guo-Ming Chen; Tian-Qi Luo; Zhi-Wei Zhou; Yuan-Fang Li
Journal:  Aging (Albany NY)       Date:  2019-12-03       Impact factor: 5.682
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.